Targeting progressive multiple sclerosis: Toward mechanism‐informed precision medicine
Open Access
- 21 July 2026
- journal article
- review article
- Published by Wiley in Journal of Internal Medicine
- Vol. 300 (3) , 238-257
Abstract
Multiple sclerosis has undergone a therapeutic revolution over the past three decades. Randomized clinical trials and real‐world data demonstrate that modern disease‐modifying therapies substantially reduce relapse rates and acute inflammatory activity detected by magnetic resonance imaging (MRI). However, disability accumulation increasingly occurs independent of relapse activity, highlighting progression biology as the principal unmet need. Converging epidemiological and molecular evidence supports a pivotal role for Epstein–Barr virus (EBV) infection in disease initiation, whereas later stages appear dominated by brain‐intrinsic mechanisms, including compartmentalized inflammation, microglial activation, failure of remyelination and accelerated biological ageing. Population‐based cohorts demonstrate that early high‐efficacy therapy improves long‐term outcomes, yet the risk of progression rises markedly after midlife despite effective relapse suppression. Emerging biomarkers, such as serum neurofilament light chain, glial fibrillary acidic protein, paramagnetic rim lesions and advanced quantitative MRI metrics, now enable more granular monitoring of progressive pathology. Integration of imaging, fluid biomarkers, genetics and machine learning offers opportunities for individualized benefit–risk stratification. Brain‐penetrant Bruton's tyrosine kinase inhibitors, CD40 ligand‐targeting biologics, refined B‐cell‐depleting strategies and emerging chimeric antigen receptor T‐cell therapies represent promising approaches to target different aspects of compartmentalized inflammation and smoldering disease biology. Future management will require mechanism‐informed treatment algorithms that align therapeutic choice with dominant disease drivers while incorporating comorbidity management, de‐escalation strategies and potential EBV‐targeted preventive approaches to optimize outcomes across the entire disease course.Keywords
This publication has 154 references indexed in Scilit:
- Serum Neurofilament Light Chain in Multiple Sclerosis: Superiority of Age‐ and BMI ‐Corrected Z Scores/Percentiles Over Absolute Cutoff Values for Prediction of Treatment ResponseAnnals of Clinical and Translational Neurology, 2025
- Emerging Cerebrospinal Fluid Biomarkers of Disease Activity and Progression in Multiple SclerosisJAMA Neurology, 2024
- Neurofilament Light Chain Elevation and Disability Progression in Multiple SclerosisJAMA Neurology, 2023
- Harmonizing Definitions for Progression Independent of Relapse Activity in Multiple SclerosisJAMA Neurology, 2023
- Diagnosis and Treatment of Multiple SclerosisJAMA, 2021
- Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical TrialsJAMA Neurology, 2020
- Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable TherapiesJAMA Neurology, 2020
- Association of Continuous Assessment of Step Count by Remote Monitoring With Disability Progression Among Adults With Multiple SclerosisJAMA Network Open, 2019
- Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple SclerosisJAMA Neurology, 2017
- Effect of Smoking Cessation on Multiple Sclerosis PrognosisJAMA Neurology, 2015